<DOC>
	<DOCNO>NCT00860977</DOCNO>
	<brief_summary>This study multicentre , randomize , placebo-controlled , fully blind , clinical trial twice daily oral valacyclovir 500mg versus placebo goal delay need initiate HAART among HIV infect individual neither use require HAART , use chronic suppressive anti-HSV therapy least 6 month prior study initiation .</brief_summary>
	<brief_title>Can Valacyclovir Delay Need Initiation Human Immunodeficiency Virus ( HIV ) Treatment HIV-infected Individuals ?</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>adult ( age 18 year old per Local/Provincial Guidelines ) document HIV1 infection ( determine EIA Western blot , site ' standard assay acceptable approve advance PIs study , Dr. Darrell Tan and/or Dr. Sharon Walmsley ) use chronic antiHSV therapy past 6 month , anticipate require chronic antiHSV therapy study antiretroviral naïve ( 14 day total prior ARV exposure ) CD4 count within 400900 cells/mm3 range ( inclusive ) two consecutive occasion , least one measurement within 30 day initiate trial ( baseline visit ) meet recommendation initiate ARV therapy accord current guideline pregnancy actively plan become pregnant receive chemotherapy , chronic steroid therapy immunomodulatory medication ( e.g . interferon , azathioprine , methotrexate , TNFalpha antagonists , etc . ) Estimated creatinine clearance &lt; 30 mL/min Other medical condition likely cause death within 24 month Enrolled therapeutic HIV vaccine immunotherapy trial Enrolled another trial investigate impact another intervention HIV disease progression HIV elite controller ( EC ) , phenotypically define document duration HIV infection ≥5 year , persistent CD4 cell count ≥500 cells/mm3 , persistent plasma HIV viral load &lt; 1000 copies/mL absence antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Herpes simplex virus type II</keyword>
	<keyword>Genital herpes</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>